This study aimed to develop clinically feasible models of limited sampling strategy (LSS) for estimation of the area under the concentration–time curve (AUC24h) for isoniazid, that could be applied easily in daily clinical practice for dosage adjustment in adult patients with tuberculosis. Isoniazid plasma concentrations (n = 1665) from 185 adult tuberculous patients were used for the development and validation of LSS models to estimate AUC24h following administration of the standard 5 mg/kg dose of isoniazid. Population pharmacokinetic analysis for appropriate estimation of isoniazid pharmacokinetic parameters was performed in a modelling group (n = 100). The Bayesian estimates of AUC24h (AUCref) obtained for each individual were used as the dependent variable in the regression analysis for the development of various LSS models. The LSS models were validated in a separate cohort (n = 85). Several three and four time point LSS models were built and tested. Model H (AUC24h = −1.88 + 1.05 × C1 + 0.78 × C2 + 9.44 × C5) and Model I (AUC24h= −0.65 + 1.00 × C1 + 1.94 × C2 + 15.45 × C9) had the best performances [adj-R2 = 0.93, median prediction error (MPE) = −0.20, root median squared prediction error (RMSE) = 4.65 for Model H; adj-R2 = 0.96, MPE = −0.05 RMSE = 3.56 for Model I]. The very high R2 values (≥0.94) of these regression equations in the validation cohort confirmed their high reliability. These LSS models could be applied in the context of therapeutic drug monitoring programmes aiming to personalize isoniazid dosing regimens for adult patients with tuberculosis.

Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis

ISOLA, Miriam;PEA, Federico
2017-01-01

Abstract

This study aimed to develop clinically feasible models of limited sampling strategy (LSS) for estimation of the area under the concentration–time curve (AUC24h) for isoniazid, that could be applied easily in daily clinical practice for dosage adjustment in adult patients with tuberculosis. Isoniazid plasma concentrations (n = 1665) from 185 adult tuberculous patients were used for the development and validation of LSS models to estimate AUC24h following administration of the standard 5 mg/kg dose of isoniazid. Population pharmacokinetic analysis for appropriate estimation of isoniazid pharmacokinetic parameters was performed in a modelling group (n = 100). The Bayesian estimates of AUC24h (AUCref) obtained for each individual were used as the dependent variable in the regression analysis for the development of various LSS models. The LSS models were validated in a separate cohort (n = 85). Several three and four time point LSS models were built and tested. Model H (AUC24h = −1.88 + 1.05 × C1 + 0.78 × C2 + 9.44 × C5) and Model I (AUC24h= −0.65 + 1.00 × C1 + 1.94 × C2 + 15.45 × C9) had the best performances [adj-R2 = 0.93, median prediction error (MPE) = −0.20, root median squared prediction error (RMSE) = 4.65 for Model H; adj-R2 = 0.96, MPE = −0.05 RMSE = 3.56 for Model I]. The very high R2 values (≥0.94) of these regression equations in the validation cohort confirmed their high reliability. These LSS models could be applied in the context of therapeutic drug monitoring programmes aiming to personalize isoniazid dosing regimens for adult patients with tuberculosis.
File in questo prodotto:
File Dimensione Formato  
Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Non pubblico
Dimensione 649.54 kB
Formato Adobe PDF
649.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1112692
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact